Annual CFF
-$7.09 B
+$545.00 M+7.14%
31 December 2023
Summary:
Abbott Laboratories annual cash flow from financing activities is currently -$7.09 billion, with the most recent change of +$545.00 million (+7.14%) on 31 December 2023. During the last 3 years, it has fallen by -$4.31 billion (-155.16%). ABT annual CFF is now -163.61% below its all-time high of $11.15 billion, reached on 31 December 2016.ABT Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$1.58 B
-$785.00 M-99.24%
30 September 2024
Summary:
Abbott Laboratories quarterly cash flow from financing activities is currently -$1.58 billion, with the most recent change of -$785.00 million (-99.24%) on 30 September 2024. Over the past year, it has increased by +$764.00 million (+32.65%). ABT quarterly CFF is now -111.67% below its all-time high of $13.50 billion, reached on 31 December 2016.ABT Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$5.59 B
+$764.00 M+12.01%
30 September 2024
Summary:
Abbott Laboratories TTM cash flow from financing activities is currently -$5.59 billion, with the most recent change of +$764.00 million (+12.01%) on 30 September 2024. Over the past year, it has increased by +$901.00 million (+13.87%). ABT TTM CFF is now -150.19% below its all-time high of $11.15 billion, reached on 31 December 2016.ABT TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ABT Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +7.1% | +32.6% | +13.9% |
| 3 y3 years | -155.2% | -14.4% | -27.3% |
| 5 y5 years | +31.8% | -207.2% | +18.7% |
ABT Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -155.2% | +7.1% | -99.2% | +58.8% | -27.3% | +33.0% |
| 5 y | 5 years | -155.2% | +31.8% | -339.5% | +58.8% | -101.6% | +33.0% |
| alltime | all time | -163.6% | +31.8% | -111.7% | +75.6% | -150.2% | +46.2% |
Abbott Laboratories Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$1.58 B(+99.2%) | -$5.59 B(-12.0%) |
| June 2024 | - | -$791.00 M(-32.7%) | -$6.36 B(-7.3%) |
| Mar 2024 | - | -$1.18 B(-42.7%) | -$6.86 B(-3.3%) |
| Dec 2023 | -$7.09 B(-7.1%) | -$2.05 B(-12.3%) | -$7.09 B(+9.2%) |
| Sept 2023 | - | -$2.34 B(+81.5%) | -$6.50 B(+14.0%) |
| June 2023 | - | -$1.29 B(-8.6%) | -$5.70 B(+9.1%) |
| Mar 2023 | - | -$1.41 B(-3.2%) | -$5.22 B(-31.6%) |
| Dec 2022 | -$7.64 B(+39.0%) | -$1.46 B(-5.6%) | -$7.64 B(-5.3%) |
| Sept 2022 | - | -$1.54 B(+89.8%) | -$8.06 B(+2.1%) |
| June 2022 | - | -$813.00 M(-78.7%) | -$7.90 B(-5.4%) |
| Mar 2022 | - | -$3.82 B(+102.7%) | -$8.35 B(+52.0%) |
| Dec 2021 | -$5.49 B(+97.7%) | -$1.89 B(+37.0%) | -$5.49 B(+25.0%) |
| Sept 2021 | - | -$1.38 B(+8.9%) | -$4.39 B(-10.9%) |
| June 2021 | - | -$1.26 B(+30.7%) | -$4.93 B(+63.8%) |
| Mar 2021 | - | -$967.00 M(+22.9%) | -$3.01 B(+8.3%) |
| Dec 2020 | -$2.78 B(-35.2%) | -$787.00 M(-58.9%) | -$2.78 B(-33.5%) |
| Sept 2020 | - | -$1.92 B(-391.0%) | -$4.18 B(+50.5%) |
| June 2020 | - | $658.00 M(-189.5%) | -$2.77 B(-28.5%) |
| Mar 2020 | - | -$735.00 M(-66.4%) | -$3.88 B(-9.5%) |
| Dec 2019 | -$4.29 B(-58.7%) | -$2.19 B(+325.9%) | -$4.29 B(-37.7%) |
| Sept 2019 | - | -$513.00 M(+14.3%) | -$6.88 B(+76.6%) |
| June 2019 | - | -$449.00 M(-60.7%) | -$3.90 B(-23.3%) |
| Mar 2019 | - | -$1.14 B(-76.1%) | -$5.08 B(-51.1%) |
| Dec 2018 | -$10.39 B(+96.8%) | -$4.78 B(-293.3%) | -$10.39 B(+81.4%) |
| Sept 2018 | - | $2.47 B(-251.5%) | -$5.73 B(-33.3%) |
| June 2018 | - | -$1.63 B(-74.7%) | -$8.58 B(+17.0%) |
| Mar 2018 | - | -$6.46 B(+5663.4%) | -$7.34 B(+38.9%) |
| Dec 2017 | -$5.28 B(-147.4%) | -$112.00 M(-71.0%) | -$5.28 B(-163.4%) |
| Sept 2017 | - | -$386.00 M(+0.5%) | $8.34 B(+4.5%) |
| June 2017 | - | -$384.00 M(-91.3%) | $7.97 B(-2.5%) |
| Mar 2017 | - | -$4.40 B(-132.6%) | $8.18 B(-26.6%) |
| Dec 2016 | $11.15 B(-598.5%) | $13.50 B(-1910.2%) | $11.15 B(-490.6%) |
| Sept 2016 | - | -$746.00 M(+316.8%) | -$2.85 B(-2.4%) |
| June 2016 | - | -$179.00 M(-87.5%) | -$2.92 B(-6.3%) |
| Mar 2016 | - | -$1.43 B(+188.1%) | -$3.12 B(+39.4%) |
| Dec 2015 | -$2.24 B(-18.5%) | -$497.00 M(-39.0%) | -$2.24 B(-8.3%) |
| Sept 2015 | - | -$815.00 M(+117.9%) | -$2.44 B(+28.7%) |
| June 2015 | - | -$374.00 M(-32.0%) | -$1.90 B(-11.4%) |
| Mar 2015 | - | -$550.00 M(-21.4%) | -$2.14 B(-22.0%) |
| Dec 2014 | -$2.74 B(-59.1%) | -$700.00 M(+158.3%) | -$2.74 B(-29.9%) |
| Sept 2014 | - | -$271.00 M(-56.2%) | -$3.91 B(-6.9%) |
| June 2014 | - | -$619.00 M(-46.3%) | -$4.20 B(+34.8%) |
| Mar 2014 | - | -$1.15 B(-38.4%) | -$3.12 B(-53.5%) |
| Dec 2013 | -$6.70 B(-3533.8%) | -$1.87 B(+234.3%) | -$6.70 B(+188.4%) |
| Sept 2013 | - | -$559.00 M(-220.2%) | -$2.32 B(-46.7%) |
| June 2013 | - | $465.00 M(-109.8%) | -$4.35 B(-7.4%) |
| Mar 2013 | - | -$4.73 B(-288.9%) | -$4.70 B(-2511.9%) |
| Dec 2012 | $195.00 M(-103.0%) | $2.51 B(-196.7%) | $195.00 M(-104.9%) |
| Sept 2012 | - | -$2.59 B(-2345.8%) | -$3.99 B(-1.9%) |
| June 2012 | - | $115.37 M(-30.2%) | -$4.07 B(-26.9%) |
| Mar 2012 | - | $165.22 M(-109.8%) | -$5.57 B(-13.2%) |
| Dec 2011 | -$6.42 B(+490.5%) | -$1.68 B(-36.9%) | -$6.42 B(+32.9%) |
| Sept 2011 | - | -$2.67 B(+92.5%) | -$4.83 B(+69.5%) |
| June 2011 | - | -$1.39 B(+102.6%) | -$2.85 B(+127.7%) |
| Mar 2011 | - | -$684.33 M(+633.4%) | -$1.25 B(+15.1%) |
| Dec 2010 | -$1.09 B(-208.6%) | -$93.31 M(-86.4%) | -$1.09 B(+121.5%) |
| Sept 2010 | - | -$687.11 M(-422.8%) | -$491.05 M(-25.6%) |
| June 2010 | - | $212.88 M(-140.9%) | -$660.28 M(-45.1%) |
| Mar 2010 | - | -$520.20 M(-203.3%) | -$1.20 B(-220.0%) |
| Dec 2009 | $1.00 B(-128.7%) | $503.37 M(-158.8%) | $1.00 B(+83.3%) |
| Sept 2009 | - | -$856.33 M(+159.8%) | $546.52 M(-127.9%) |
| June 2009 | - | -$329.62 M(-119.6%) | -$1.96 B(+24.6%) |
| Mar 2009 | - | $1.68 B(+3418.8%) | -$1.58 B(-54.8%) |
| Dec 2008 | -$3.49 B(+50.7%) | $47.88 M(-101.4%) | -$3.49 B(-12.6%) |
| Sept 2008 | - | -$3.37 B(-5933.9%) | -$3.99 B(+176.6%) |
| June 2008 | - | $57.68 M(-125.5%) | -$1.44 B(-29.0%) |
| Mar 2008 | - | -$226.27 M(-50.4%) | -$2.03 B(-12.1%) |
| Dec 2007 | -$2.31 B | -$455.78 M(-44.3%) | -$2.31 B(-405.8%) |
| Sept 2007 | - | -$817.97 M(+53.7%) | $756.24 M(+94.4%) |
| June 2007 | - | -$532.22 M(+5.0%) | $389.04 M(-91.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2007 | - | -$506.66 M(-119.4%) | $4.57 B(+26.1%) |
| Dec 2006 | $3.62 B(-239.7%) | $2.61 B(-320.5%) | $3.62 B(+1036.9%) |
| Sept 2006 | - | -$1.19 B(-132.5%) | $318.58 M(-82.3%) |
| June 2006 | - | $3.64 B(-351.3%) | $1.80 B(-149.9%) |
| Mar 2006 | - | -$1.45 B(+110.1%) | -$3.61 B(+39.3%) |
| Dec 2005 | -$2.59 B(+491.4%) | -$690.26 M(-330.2%) | -$2.59 B(+22.6%) |
| Sept 2005 | - | $299.79 M(-116.9%) | -$2.11 B(-38.0%) |
| June 2005 | - | -$1.77 B(+311.2%) | -$3.41 B(+272.9%) |
| Mar 2005 | - | -$430.72 M(+102.4%) | -$914.38 M(+108.6%) |
| Dec 2004 | -$438.32 M(-78.2%) | -$212.83 M(-78.6%) | -$438.32 M(-61.0%) |
| Sept 2004 | - | -$995.05 M(-237.4%) | -$1.12 B(+1529.2%) |
| June 2004 | - | $724.22 M(+1497.3%) | -$68.95 M(-95.6%) |
| Mar 2004 | - | $45.34 M(-105.0%) | -$1.55 B(-22.7%) |
| Dec 2003 | -$2.01 B(-13.2%) | -$897.95 M(-1610.9%) | -$2.01 B(+0.8%) |
| Sept 2003 | - | $59.43 M(-107.8%) | -$1.99 B(-14.2%) |
| June 2003 | - | -$758.52 M(+85.4%) | -$2.32 B(+9.7%) |
| Mar 2003 | - | -$409.18 M(-53.6%) | -$2.11 B(-8.5%) |
| Dec 2002 | -$2.31 B(-150.0%) | -$881.67 M(+225.9%) | -$2.31 B(+40.3%) |
| Sept 2002 | - | -$270.51 M(-51.0%) | -$1.65 B(-20.0%) |
| June 2002 | - | -$552.56 M(-8.7%) | -$2.06 B(+68.6%) |
| Mar 2002 | - | -$605.24 M(+177.3%) | -$1.22 B(-126.4%) |
| Dec 2001 | $4.62 B(-315.3%) | -$218.22 M(-68.0%) | $4.62 B(+6.2%) |
| Sept 2001 | - | -$682.60 M(-339.8%) | $4.36 B(-1.7%) |
| June 2001 | - | $284.69 M(-94.6%) | $4.43 B(+34.6%) |
| Mar 2001 | - | $5.24 B(-1177.4%) | $3.29 B(-253.4%) |
| Dec 2000 | -$2.15 B(+50.5%) | -$486.35 M(-19.7%) | -$2.15 B(+44.1%) |
| Sept 2000 | - | -$605.54 M(-29.1%) | -$1.49 B(+15.1%) |
| June 2000 | - | -$854.04 M(+322.7%) | -$1.29 B(+33.5%) |
| Mar 2000 | - | -$202.03 M(-217.8%) | -$969.23 M(-32.1%) |
| Dec 1999 | -$1.43 B(+15.7%) | $171.46 M(-141.8%) | -$1.43 B(-12.7%) |
| Sept 1999 | - | -$409.76 M(-22.5%) | -$1.63 B(+0.7%) |
| June 1999 | - | -$528.91 M(-19.8%) | -$1.62 B(+32.1%) |
| Mar 1999 | - | -$659.59 M(+1773.8%) | -$1.23 B(-0.4%) |
| Dec 1998 | -$1.23 B(-4.3%) | -$35.20 M(-91.2%) | -$1.23 B(-13.5%) |
| Sept 1998 | - | -$397.98 M(+194.3%) | -$1.43 B(+5.0%) |
| June 1998 | - | -$135.22 M(-79.7%) | -$1.36 B(-3.2%) |
| Mar 1998 | - | -$664.80 M(+192.0%) | -$1.40 B(+8.8%) |
| Dec 1997 | -$1.29 B(+117.6%) | -$227.70 M(-31.0%) | -$1.29 B(+1.6%) |
| Sept 1997 | - | -$330.11 M(+83.6%) | -$1.27 B(-1.2%) |
| June 1997 | - | -$179.84 M(-67.4%) | -$1.28 B(+169.1%) |
| Mar 1997 | - | -$551.36 M(+166.5%) | -$477.15 M(-19.4%) |
| Dec 1996 | -$592.30 M(-36.6%) | -$206.85 M(-40.2%) | -$592.30 M(-7.6%) |
| Sept 1996 | - | -$346.14 M(-155.2%) | -$640.97 M(+33.2%) |
| June 1996 | - | $627.20 M(-194.1%) | -$481.04 M(-65.3%) |
| Mar 1996 | - | -$666.50 M(+160.8%) | -$1.38 B(+48.3%) |
| Dec 1995 | -$933.87 M(-27.0%) | -$255.53 M(+37.2%) | -$933.87 M(-7.5%) |
| Sept 1995 | - | -$186.21 M(-32.7%) | -$1.01 B(-7.6%) |
| June 1995 | - | -$276.61 M(+28.3%) | -$1.09 B(+4.7%) |
| Mar 1995 | - | -$215.53 M(-35.0%) | -$1.04 B(-18.4%) |
| Dec 1994 | -$1.28 B(+48.2%) | -$331.37 M(+23.0%) | -$1.28 B(+10.8%) |
| Sept 1994 | - | -$269.51 M(+18.4%) | -$1.15 B(+0.6%) |
| June 1994 | - | -$227.64 M(-49.6%) | -$1.15 B(+8.9%) |
| Mar 1994 | - | -$451.41 M(+118.7%) | -$1.05 B(+22.1%) |
| Dec 1993 | -$863.87 M(+31.4%) | -$206.37 M(-21.6%) | -$863.87 M(+7.1%) |
| Sept 1993 | - | -$263.10 M(+96.2%) | -$806.60 M(+39.2%) |
| June 1993 | - | -$134.10 M(-48.5%) | -$579.40 M(-32.2%) |
| Mar 1993 | - | -$260.30 M(+74.6%) | -$854.80 M(+30.0%) |
| Dec 1992 | -$657.50 M(-15.7%) | -$149.10 M(+315.3%) | -$657.50 M(-0.7%) |
| Sept 1992 | - | -$35.90 M(-91.2%) | -$661.90 M(-23.5%) |
| June 1992 | - | -$409.50 M(+550.0%) | -$865.70 M(+40.2%) |
| Mar 1992 | - | -$63.00 M(-59.0%) | -$617.40 M(-20.8%) |
| Dec 1991 | -$779.80 M(+39.7%) | -$153.50 M(-36.0%) | -$779.80 M(-26.9%) |
| Sept 1991 | - | -$239.70 M(+48.7%) | -$1.07 B(+13.5%) |
| June 1991 | - | -$161.20 M(-28.5%) | -$939.80 M(+15.4%) |
| Mar 1991 | - | -$225.40 M(-48.8%) | -$814.50 M(+45.9%) |
| Dec 1990 | -$558.20 M(-40.4%) | -$440.10 M(+289.1%) | -$558.20 M(+372.7%) |
| Sept 1990 | - | -$113.10 M(+215.0%) | -$118.10 M(+2262.0%) |
| June 1990 | - | -$35.90 M(-216.2%) | -$5.00 M(-116.2%) |
| Mar 1990 | - | $30.90 M | $30.90 M |
| Dec 1989 | -$935.90 M | - | - |
FAQ
- What is Abbott Laboratories annual cash flow from financing activities?
- What is the all time high annual CFF for Abbott Laboratories?
- What is Abbott Laboratories annual CFF year-on-year change?
- What is Abbott Laboratories quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Abbott Laboratories?
- What is Abbott Laboratories quarterly CFF year-on-year change?
- What is Abbott Laboratories TTM cash flow from financing activities?
- What is the all time high TTM CFF for Abbott Laboratories?
- What is Abbott Laboratories TTM CFF year-on-year change?
What is Abbott Laboratories annual cash flow from financing activities?
The current annual CFF of ABT is -$7.09 B
What is the all time high annual CFF for Abbott Laboratories?
Abbott Laboratories all-time high annual cash flow from financing activities is $11.15 B
What is Abbott Laboratories annual CFF year-on-year change?
Over the past year, ABT annual cash flow from financing activities has changed by +$545.00 M (+7.14%)
What is Abbott Laboratories quarterly cash flow from financing activities?
The current quarterly CFF of ABT is -$1.58 B
What is the all time high quarterly CFF for Abbott Laboratories?
Abbott Laboratories all-time high quarterly cash flow from financing activities is $13.50 B
What is Abbott Laboratories quarterly CFF year-on-year change?
Over the past year, ABT quarterly cash flow from financing activities has changed by +$764.00 M (+32.65%)
What is Abbott Laboratories TTM cash flow from financing activities?
The current TTM CFF of ABT is -$5.59 B
What is the all time high TTM CFF for Abbott Laboratories?
Abbott Laboratories all-time high TTM cash flow from financing activities is $11.15 B
What is Abbott Laboratories TTM CFF year-on-year change?
Over the past year, ABT TTM cash flow from financing activities has changed by +$901.00 M (+13.87%)